Clinical Trials | December 04, 2025
Eli Lilly pledges $40 million to Indiana University to expand clinical trials
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Angelini Ventures has already invested €125 million in 22 startups
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GV20 received an upfront payment and is eligible for additional milestone payments
Subscribe To Our Newsletter & Stay Updated
